RT Book, Section A1 Kalkhoran, Sara A1 Glantz, Stanton A2 Fuster, Valentin A2 Harrington, Robert A. A2 Narula, Jagat A2 Eapen, Zubin J. SR Print(0) ID 1191187223 T1 PREVENTING AND MITIGATING SMOKING-RELATED HEART DISEASE T2 Hurst's The Heart, 14e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9780071843249 LK accesscardiology.mhmedical.com/content.aspx?aid=1191187223 RD 2024/03/29 AB SummaryThis chapter discusses the prevention of smoking-related heart disease. Smoking cessation results in an immediate reduction in risk of cardiac events, which continues to decline rapidly. For example, the smoking-related excess risk of myocardial infarction is halved by a year after smoking cessation. The US Public Health Service recommends that all patients be asked about their tobacco use on a regular basis and that those patients who do smoke are advised to quit and are assisted in quitting (see accompanying Hurst’s Central Illustration). Notably, intensive physician advice to quit smoking is associated with a higher rate of smoking cessation than no or minimal advice to quit. Pharmacotherapy and counselling are effective treatments for smoking cessation, particularly when combined. First-line pharmacotherapies include nicotine-replacement therapy (available in the form of patches, gum, lozenges, inhalers, and nasal sprays), varenicline, and bupropion. The efficacy of electronic cigarettes (e-cigarettes) for smoking cessation and their long-term health effects are not well established, and “real world” data indicate that these devices are associated with less quitting than nicotine-replacement therapy or no cessation aids. Tobacco control policies, such as smoke-free workplaces and public places, have had a substantial role in reducing smoking prevalence as well as exposure to secondhand smoke in countries such as the United States and the United Kingdom.